NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Sarepta Therapeutics, Inc. (NASDSAQ:SRPT)
Class Period: September 6, 2017 – August 19, 2019

Deadline: October 29, 2019
For more info:www.bgandg.com/srpt

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) golodirsen posed significant safety risks to patients; (2) consequently, the NDA package for golodirsen's accelerated approval was unlikely to receive FDA approval; and (3) as a result, Sarepta's public statements were materially false and misleading at all relevant times.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Class Period: May 8, 2018 – June 20, 2019

Deadline: October 30, 2019
For more info:www.bgandg.com/acrs

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) the Company's advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales; (2) as a result, the Company was reasonably likely to face regulatory scrutiny; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Canada Goose Holdings Inc. (NYSE:GOOS)

Class Period: March 16, 2017 – August 1, 2019

Deadline: November 4, 2019
For more info:www.bgandg.com/goos

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Canada Goose sourced the down and fur used in its clothing products in a way that treated animals in an unethical and inhumane manner; (2) Canada Goose was thus non-compliant with relevant FTC regulations pertaining to false advertising with respect to its sourcing practices; (3) accordingly, Canada Goose was the subject of an ongoing FTC investigation regarding false advertising; and (4) consequently, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560614

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

International Flavors & Fragrances Inc. (NYSE:IFF)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/international-flavors-fragrances-inc-loss-submission-form?prid=3733&wire=1
Lead Plaintiff Deadline: October 11, 2019
Class Period: May 7, 2018 to August 5, 2019

Allegations against IFF include that: (1) Frutarom Industries Ltd. ("Frutarom"), which the Company acquired in 2018, had bribed customers in Russia and Ukraine; (2) senior management at Frutarom were aware of such improper payments; (3) as a result, Frutarom's financial results were materially overstated; (4) as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) the Company had not completed adequate due diligence before acquiring Frutarom; (6) as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

NetApp, Inc. (NASDAQGS:NTAP)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/netapp-inc-loss-submission-form?prid=3733&wire=1
Lead Plaintiff Deadline: October 15, 2019
Class Period: May 22, 2019 to August 1, 2019

Allegations against NTAP include that: (1) the Company was unable to close large deals within the quarter and that the deals were pushed out to subsequent quarters or downsized; (2) as a result, the Company's revenue would be materially impacted; (3) as a result, the Company would lower its fiscal 2020 guidance; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Evolent Health, Inc. (NYSE:EVH)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/evolent-health-inc-loss-submission-form?prid=3733&wire=1
Lead Plaintiff Deadline: October 7, 2019
Class Period: March 3, 2017 to May 28, 2019

Allegations against EVH include that: (1) Evolent's partnership model was not aligned with its partners, as it was designed to parasitically increase its own revenue by extracting enormous administrative and management fees at the expense of its partners such as Passport Health Plan ("Passport"); (2) Passport was struggling financially, particularly after Kentucky cut its reimbursement rates, and the partnership between Evolent and Passport was becoming increasingly unsustainable; (3) Evolent was draining Passport of functions, employees, and money to such an extent that Passport was left on the verge of insolvency; (4) for several months, Passport was conducting a bidding process to sell itself to a financial buyer to prevent liquidation; and (5) as a result of the foregoing, Defendants public statements were materially false and/or misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 561267

CEDARHURST, NY / ACCESSWIRE / September 27, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Abiomed, Inc. (NASDAQGS:ABMD)

Investors Affected : January 31, 2019 – July 31, 2019

A class action has commenced on behalf of certain shareholders in Abiomed, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Abiomed's revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company's prior projections and market expectations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/abiomed-inc-loss-submission-form/?id=3732&from=1

CVS Health Corporation (NYSE:CVS)

Investors Affected : on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for their Aetna shares in connection with CVS's acquisition of Aetna on November 28, 2018.

A class action has commenced on behalf of certain shareholders in CVS Health Corporation. According to the filed complaint, CVS made false and/or misleading statements in connection with its acquisition of Aetna and/or failed to disclose that: (a) by the end of 2017, CVS's financial condition and expected earnings had deteriorated as a result of rising costs and poor results being experienced in the long-term care ("LTC") unit associated with the 2015 acquisition of Omnicare; (b) in 2017, deteriorating conditions and prospects in CVS 's LTC unit prompted CVS to undertake hasty acquisitions of LTC pharmacies to compensate for the declining LTC business and/or mask the expected LTC goodwill impairment ahead of the planned Acquisition; (c) although negative LTC performance factors prompted CVS and the CVS Individual Defendants to make hasty LTC pharmacy acquisitions in 2017, those same negative factors were being overlooked and ignored for purposes of undertaking, disclosing, and reporting the results of LTC goodwill impairment tests throughout 2017, in violation of GAAP; (d) the LTC goodwill being carried on CVS's books as a result of the Omnicare acquisition was being carried at inflated values that would require billions of dollars in impairment charges that would be charged against earnings; and (e) as a result of the foregoing, CVS's true business metrics and financial prospects were not as the Offering Documents represented.

Shareholders may find more information at https://kclasslaw.com/securities/cvs-health-corporation-loss-submission-form-2/?id=3732&from=1

MacroGenics, Inc. (NASDAQGS:MGNX)

Investors Affected : February 6, 2019 – June 3, 2019

A class action has commenced on behalf of certain shareholders in MacroGenics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.

Shareholders may find more information at https://kclasslaw.com/securities/macrogenics-inc-loss-submission-form/?id=3732&from=1

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

SOURCE: Kuznicki Law PLLC

ReleaseID: 561266

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Sundial Growers Inc. (NASDAQ:SNDL)
Class Period: pursuant and/or traceable to the registration statement issued in connection with Sundial's August 1, 2019 initial public stock offering.
Lead Plaintiff Deadline: November 25, 2019

The lawsuit alleges Sundial Growers Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) Sundial failed to supply saleable cannabis in line with contractual obligations to Zenabis Global Inc.; (2) due to material quality issues, Zenabis had to return or reject a total of 554 kg of cannabis to Sundial, valued at approximately U.S. $1.9 million (C$2.5 million); and (3) as a result, defendants' statements about Sundial's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in SNDL: http://www.kleinstocklaw.com/pslra-1/sundial-growers-inc-loss-submission-form?id=3731&from=1

Meredith Corporation (NYSE:MDP)
Class Period: January 31, 2018 to September 5, 2019
Lead Plaintiff Deadline: November 5, 2019

The lawsuit alleges that Meredith Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Time, Inc. acquisition was not as profitable as the Company had claimed; (2) the Company would incur additional costs for strategic investments to improve the Time business; (3) as a result, the Company's earnings would be materially and adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in MDP: http://www.kleinstocklaw.com/pslra-1/meredith-corporation-loss-submission-form?id=3731&from=1

Viewray, Inc. (NASDAQ:VRAY)
Class Period: March 15, 2019 to August 8, 2019
Lead Plaintiff Deadline: November 12, 2019

The complaint alleges that during the class period Viewray, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) demand for ViewRay systems had declined due in part to changes being made to Medicare reimbursement approaches first announced in November 2019 that could make purchases of new ViewRay systems less profitable for customers; (b) the Company's reported backlog was overstated due to the inclusion of orders with insufficient surety as to permit for their inclusion in reported backlog; and (c) as a result of the foregoing, defendants' positive statements about ViewRay's business metrics and financial prospects during the Class Period were materially false and misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in VRAY: http://www.kleinstocklaw.com/pslra-1/viewray-inc-loss-submission-form?id=3731&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 561265

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Venator Materials PLC (NYSE:VNTR)

Lawsuit on behalf of: investors who purchased (a) between August 2, 2017 and October 29, 2018, inclusive; (b) in or traceable to the Company's initial public offering conducted on or around August 3, 2017; and (c) in or traceable to the Company's secondary public offering conducted on or around December 4, 2017.
Lead Plaintiff Deadline : September 30, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/venator-materials-plc-loss-form?prid=3730&wire=1

According to the filed complaint, (a) the fire damage at the Pori facility was far more extensive than disclosed to investors, rendering the facility beyond repair; (b) the true cost of the Pori facility fire exceeded $1 billion, hundreds of millions of dollars beyond the limits of the Company's insurance policy; (c) the Company was paying rebuilding premiums, and thereby incurring tens of millions of dollars in additional costs, in a futile attempt to expedite the rehabilitation process; (d) Venator had lost, essentially without prospect of rehabilitation, 80% of the production capacity of the Pori facility, and thus lost a substantial portion of one of its largest revenue producing assets; and (e) the Company's reported annual Titanium Dioxide production capacity had been inflated by approximately 104,000 metric tons, or 15%.

GTT Communications, Inc. (NYSE:GTT)

Lawsuit on behalf of: investors who purchased February 26, 2018 – July 1, 2019
Lead Plaintiff Deadline : September 30, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/gtt-communications-inc-loss-form?prid=3730&wire=1

According to the filed complaint, during the class period, GTT Communications, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) following GTT's acquisition of Interoute Communications Holdings S.A., there were delays in migrating Interoute's legacy systems and processes into GTT's client management database system; (2) Interoute had made a strategic priority shift to sell cloud services that was a higher percentage of Interoute's sales in the two years leading up to the acquisition; (3) a material percentage of the Interoute sales representatives were not productive at selling GTT's core cloud networking services; (4) GTT was unable to yield as many Interoute salespeople because Interoute had hired many sales people focused on cloud services and allowed underperforming sales representatives to remain at Interoute; and (5) as a result of the foregoing, Defendants' public statements were materially false and/or misleading and/or lacked a reasonable basis.

Curaleaf Holdings, Inc. (OTCMKTS:CURLF)

Lawsuit on behalf of: investors who purchased November 21, 2018 – July 22, 2019
Lead Plaintiff Deadline : October 4, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/curaleaf-holdings-inc-loss-form?prid=3730&wire=1

According to the filed complaint, during the class period, Curaleaf Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 561264

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Oasmia Pharmaceutical AB ("Oasmia" or the "Company") (NASDAQ:OASM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Oasmia securities between October 23, 2015 through July 9, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/oasm.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Oasmia engaged in improper related-party transactions with Alceco International S.A. and Ardenia Investment LTD, which were controlled by Defendant Aleksov and his former father-in-law; (2) due to those transactions, millions of Swedish kronor were not accounted for in Oasmia's books; (3) transactions concerning Oasmia's patents were also "carried out in a doubtful way;" and (4) as a result of the aforementioned misconduct, defendants' statements about Oasmia's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/oasm or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Oasmia you have until September 27, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560559

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Farfetch Ltd. ("Farfetch" or the "Company") (NYSE:FTCH) and certain of its officers, on behalf of shareholders who purchased Farfetchsecurities pursuant and/or traceable to the Registration Statement and Prospectus (together, the "Registration Statement") issued in connection with Farfetch's initial public offering of ordinary shares conducted in September 2018 (the "IPO"). Such investors are encouraged to join this case by visiting the firm's site:www.bgandg.com/ftch.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) large scale online wholesale was reasonably likely to lead to pricing volatility and heavy promotions of luxury goods; (2) the Company's core business was vulnerable to such pricing pressures; (3) the Company would aggressively pursue acquisitions to remain profitable; and (4) as a result, Farfetch's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/ftch or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a lossin Farfetchyou have until November 18, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560799

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Valaris plc (NYSE:VAL)

Class Period: April 11, 2019 – July 31, 2019

Deadline: October 21, 2019
For more info:www.bgandg.com/val

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Valaris was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (2) the foregoing was reasonably likely to have a material negative impact on Valaris's second quarter 2019 results; (3) the merger leading to Valaris's establishment could not deliver on its touted benefits; and (4) as a result, Valaris's public statements were materially false and misleading at all relevant times.

Textron Inc. (NYSE:TXT)

Class Period: January 31, 2018 – October 17, 2018

Deadline: October 21, 2019
For more info:www.bgandg.com/txt

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) end-market sales of Arctic Cat Inc. products were slowing, resulting in a massive glut of old Arctic Cat inventory on dealers' floors; (2) in order to clear out this old inventory, Textron provided significant price discounts, which negatively impacted Textron's earnings; and (3) as a result, Textron's public statements were materially false and misleading at all relevant times.

AmTrust Financial Services, Inc. (OTCPINK: AFSIA, AFSIB, AFSIC, AFSIM, AFSIN, AFSIP)
Class Period: January 22, 2018 – January 18, 2019

Deadline: October 28, 2019
For more info:www.bgandg.com/afsi

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose material adverse information. Specifically, the complaint alleges that in AmTrust's 2018 merger announcement, the Company said that unlike its common shares, which were being acquired in the Buyout, the six series of publicly traded AmTrust preferred stock were not being purchased in the Merger. The complaint continues to allege that AmTrust misleadingly indicated that the preferred shares would continue to be listed on the NYSE and would remain listed and outstanding after the Merger. The complaint also alleges that conflicting to these statements, on January 18, 2019, less than two months after the Merger, AmTrust revealed it would delist all six series of AmTrust preferred stock from the NYSE. Following this announcement, the preferred stock prices dropped close to 40%.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560609